Form 8-K - Current report:
SEC Accession No. 0001213900-24-113256
Filing Date
2024-12-30
Accepted
2024-12-30 08:07:03
Documents
16
Period of Report
2024-12-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226262-8k_biora.htm   iXBRL 8-K 50379
2 DIP TERM SHEET ea022626201ex10-1_biora.htm EX-10.1 229475
3 PRESS RELEASE DATED DECEMBER 30, 2024 ea022626201ex99-1_biora.htm EX-99.1 10980
4 GRAPHIC ex99-1_001.jpg GRAPHIC 13581
  Complete submission text file 0001213900-24-113256.txt   541963

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE bior-20241227.xsd EX-101.SCH 3042
6 XBRL LABEL FILE bior-20241227_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE bior-20241227_pre.xml EX-101.PRE 22377
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0226262-8k_biora_htm.xml XML 3808
Mailing Address 4330 LA JOLLA VILLAGE DRIVE SUITE 200 SAN DIEGO CA 92122
Business Address 4330 LA JOLLA VILLAGE DRIVE SUITE 200 SAN DIEGO CA 92122 855-293-2639
BIORA THERAPEUTICS, INC. (Filer) CIK: 0001580063 (see all company filings)

EIN.: 273950390 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39334 | Film No.: 241586978
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)